LeIF-adjuvanted leishmaniasis vaccine (IDRI)
N/A
Report date: 2023/02/17 21:17:22
Base Information
Drug NameLeIF-adjuvanted leishmaniasis vaccine (IDRI)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcInfectious Disease Research Institute
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesInfectious Disease Research InstituteAccess to Advanced Health InstituteGlaxosmithkline Plc
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A